James E Kimpton1,2, Iain M Carey3, Christopher J D Threapleton1,2, Alexandra Robinson1, Tess Harris3,4, Derek G Cook3, Stephen DeWilde3,5, Emma H Baker1,6. 1. Clinical Pharmacology, St George's University Hospitals NHS Foundation Trust, London, UK. 2. Institute of Medical and Biomedical Education, St George's, University of London, UK. 3. Population Health Research Institute, St George's, University of London, UK. 4. Sonning Common Health Centre, Sonning Common, Reading, UK. 5. Lambton Road Medical Practice, Wimbledon, London, UK. 6. Institute of Infection and Immunity, St George's, University of London, UK.
Abstract
AIMS: To investigate the longitudinal exposure of English primary care patients to pharmacogenomic drugs to inform design of pre-emptive testing. METHODS: Sixty-three drugs were identified with dosing guidelines based on variants of 19 pharmacogenes in the Pharmacogenomics Knowledgebase on 01 September 2018. Prescribing of these pharmacogenomic drugs between 1993 and 2017 was summarised for a sample of 648 141 English patients aged 50-99 years on 01 January 2013, registered with Clinical Practice Research Datalink practices during 2011-12. Exposure of patients to pharmacogenomic drugs retrospectively (2, 10, 20 y) and prospectively (5 y) was described. RESULTS: During 2011-12, 58% of patients were prescribed at least 1 pharmacogenomic drug, increasing to 80% over the previous 20 years. Multiple exposure was common, with 47% patients prescribed ≥2 pharmacogenomic drugs and 7% prescribed ≥5 pharmacogenomic drugs over the next 5 years. The likelihood of exposure to pharmacogenomic drugs increased with age, with 89% patients ≥70 years prescribed at least 1 pharmacogenomic drug over the previous 20 years. Even among those aged 50-59 years, 71% were prescribed at least 1 pharmacogenomic drug over the previous 20 years. The pharmacogenomic drugs prescribed to the most patients were for pain relief, gastroprotection, psychiatric and cardiovascular conditions. Three pharmacogenes (CYP2D6, CYP2C19 and SLCO1B1) accounted for >95% pharmacogenomic drugs prescribed. CONCLUSIONS: In primary care patients, exposure to pharmacogenomic drugs is extremely common, multiplicitous and has commenced by relatively early adulthood. A small number of pharmacogenes account for the majority of drugs prescribed. These findings could inform design of pre-emptive pharmacogenomic testing for implementation in primary care.
AIMS: To investigate the longitudinal exposure of English primary care patients to pharmacogenomic drugs to inform design of pre-emptive testing. METHODS: Sixty-three drugs were identified with dosing guidelines based on variants of 19 pharmacogenes in the Pharmacogenomics Knowledgebase on 01 September 2018. Prescribing of these pharmacogenomic drugs between 1993 and 2017 was summarised for a sample of 648 141 English patients aged 50-99 years on 01 January 2013, registered with Clinical Practice Research Datalink practices during 2011-12. Exposure of patients to pharmacogenomic drugs retrospectively (2, 10, 20 y) and prospectively (5 y) was described. RESULTS: During 2011-12, 58% of patients were prescribed at least 1 pharmacogenomic drug, increasing to 80% over the previous 20 years. Multiple exposure was common, with 47% patients prescribed ≥2 pharmacogenomic drugs and 7% prescribed ≥5 pharmacogenomic drugs over the next 5 years. The likelihood of exposure to pharmacogenomic drugs increased with age, with 89% patients ≥70 years prescribed at least 1 pharmacogenomic drug over the previous 20 years. Even among those aged 50-59 years, 71% were prescribed at least 1 pharmacogenomic drug over the previous 20 years. The pharmacogenomic drugs prescribed to the most patients were for pain relief, gastroprotection, psychiatric and cardiovascular conditions. Three pharmacogenes (CYP2D6, CYP2C19 and SLCO1B1) accounted for >95% pharmacogenomic drugs prescribed. CONCLUSIONS: In primary care patients, exposure to pharmacogenomic drugs is extremely common, multiplicitous and has commenced by relatively early adulthood. A small number of pharmacogenes account for the majority of drugs prescribed. These findings could inform design of pre-emptive pharmacogenomic testing for implementation in primary care.
Authors: James E Kimpton; Iain M Carey; Christopher J D Threapleton; Alexandra Robinson; Tess Harris; Derek G Cook; Stephen DeWilde; Emma H Baker Journal: Br J Clin Pharmacol Date: 2019-12-13 Impact factor: 4.335
Authors: Selma Audi; Daniel R Burrage; Dagan O Lonsdale; Sarah Pontefract; Jamie J Coleman; Andrew W Hitchings; Emma H Baker Journal: Br J Clin Pharmacol Date: 2018-08-10 Impact factor: 4.335
Authors: J S Schildcrout; J C Denny; E Bowton; W Gregg; J M Pulley; M A Basford; J D Cowan; H Xu; A H Ramirez; D C Crawford; M D Ritchie; J F Peterson; D R Masys; R A Wilke; D M Roden Journal: Clin Pharmacol Ther Date: 2012-06-27 Impact factor: 6.875
Authors: Yuan Ji; Jennifer M Skierka; Joseph H Blommel; Brenda E Moore; Douglas L VanCuyk; Jamie K Bruflat; Lisa M Peterson; Tamra L Veldhuizen; Numrah Fadra; Sandra E Peterson; Susan A Lagerstedt; Laura J Train; Linnea M Baudhuin; Eric W Klee; Matthew J Ferber; Suzette J Bielinski; Pedro J Caraballo; Richard M Weinshilboum; John L Black Journal: J Mol Diagn Date: 2016-03-03 Impact factor: 5.568
Authors: Suzette J Bielinski; Janet E Olson; Jyotishman Pathak; Richard M Weinshilboum; Liewei Wang; Kelly J Lyke; Euijung Ryu; Paul V Targonski; Michael D Van Norstrand; Matthew A Hathcock; Paul Y Takahashi; Jennifer B McCormick; Kiley J Johnson; Karen J Maschke; Carolyn R Rohrer Vitek; Marissa S Ellingson; Eric D Wieben; Gianrico Farrugia; Jody A Morrisette; Keri J Kruckeberg; Jamie K Bruflat; Lisa M Peterson; Joseph H Blommel; Jennifer M Skierka; Matthew J Ferber; John L Black; Linnea M Baudhuin; Eric W Klee; Jason L Ross; Tamra L Veldhuizen; Cloann G Schultz; Pedro J Caraballo; Robert R Freimuth; Christopher G Chute; Iftikhar J Kullo Journal: Mayo Clin Proc Date: 2014-01 Impact factor: 7.616
Authors: M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein Journal: Clin Pharmacol Ther Date: 2012-10 Impact factor: 6.875
Authors: Henry M Dunnenberger; Kristine R Crews; James M Hoffman; Kelly E Caudle; Ulrich Broeckel; Scott C Howard; Robert J Hunkler; Teri E Klein; William E Evans; Mary V Relling Journal: Annu Rev Pharmacol Toxicol Date: 2014-10-02 Impact factor: 13.820
Authors: J Kevin Hicks; Henry M Dunnenberger; Karl F Gumpper; Cyrine E Haidar; James M Hoffman Journal: Am J Health Syst Pharm Date: 2016-12-01 Impact factor: 2.637
Authors: Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow Journal: N Engl J Med Date: 2008-02-07 Impact factor: 91.245
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: James E Kimpton; Iain M Carey; Christopher J D Threapleton; Alexandra Robinson; Tess Harris; Derek G Cook; Stephen DeWilde; Emma H Baker Journal: Br J Clin Pharmacol Date: 2019-12-13 Impact factor: 4.335
Authors: Cyrine E Haidar; Kristine R Crews; James M Hoffman; Mary V Relling; Kelly E Caudle Journal: Annu Rev Genomics Hum Genet Date: 2022-05-10 Impact factor: 9.340
Authors: Timothy A Roberts; Jennifer A Wagner; Tracy Sandritter; Benjamin T Black; Andrea Gaedigk; Stephani L Stancil Journal: Clin Transl Sci Date: 2020-10-15 Impact factor: 4.689